Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area
Oct 25, 2024 11:28 HKT | |
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）獲批進入粵港澳大灣區 為潰瘍性結腸炎患者帶來新選擇
Oct 25, 2024 11:20 HKT | |
|
云顶新耀宣布伊曲莫德（VELSIPITY）获批进入粤港澳大湾区 为溃疡性结肠炎患者带来新选择
Oct 25, 2024 11:20 HKT | |
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award'
Oct 25, 2024 09:18 HKT |  |
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024
Oct 25, 2024 08:57 HKT |  |
|
T.MAN Pharmaceutical PCL (SET: TMAN) Showcases Leadership in Health Innovation, Aiming for Sustainable Growth Following Listing on SET
Oct 23, 2024 09:00 HKT |  |
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial
Oct 22, 2024 11:52 HKT | |
|
雲頂新耀宣佈耐賦康®NefIgArd III期全球臨床試驗完整中國亞組資料的積極結果
Oct 22, 2024 11:43 HKT | |
|
云顶新耀宣布耐赋康(R) NefIgArd III期全球临床试验完整中国亚组数据的积极结果
Oct 22, 2024 11:37 HKT | |
|
Acrometa Group to Divest Its Life Sciences Business, Pursue New Business Opportunities in the Region
Oct 21, 2024 22:50 HKT |  |
|
康哲藥業入選2024年度「中國醫藥上市公司ESG競爭力」系列榜單
Oct 21, 2024 19:18 HKT | |
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy
Oct 21, 2024 12:19 HKT | |
|
云顶新耀宣布中国台湾地区药政部门批准全球首个对因治疗IgA肾病药物耐赋康®的新药上市许可申请
Oct 21, 2024 12:08 HKT | |
|
雲頂新耀宣佈中國台灣地區藥政部門批准全球首個對因治療IgA腎病藥物耐賦康®的新藥上市許可申請
Oct 21, 2024 11:44 HKT | |
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery
Oct 18, 2024 18:37 HKT | |
|
云顶新耀股价升两成 盈利潜力助力估值修复
Oct 18, 2024 18:31 HKT | |
|
雲頂新耀股價升兩成 盈利潛力助力估值修復
Oct 18, 2024 18:28 HKT | |
|
康哲藥業：蘆可替尼乳膏（白癜風）大灣區首批處方落地
Oct 18, 2024 14:54 HKT |  |
|
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
Oct 17, 2024 08:00 HKT |  |
|
Athos宣佈其人工智慧生成的全新口服G9A抑製劑ATH-063的I期臨床試驗頂線數據，顯示其對強效抗炎調節性T細胞的選擇性擴增和啟動
Oct 17, 2024 08:00 HKT | |
|